PKCθ Inhibitor HCl | CAS#2253640-49-0 | PKCθ Inhibitor

MedKoo Cat#: 112170 | Name: PKCθ Inhibitor HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PKCθ inhibitor is an inhibitor of PKCθ.

Chemical Structure

PKCθ Inhibitor HCl

CAS#2253640-49-0

Theoretical Analysis

MedKoo Cat#: 112170

Name: PKCθ Inhibitor HCl

CAS#: 2253640-49-0

Chemical Formula: C20H26ClF3N6O3

Exact Mass: 490.1707

Molecular Weight: 490.91

Elemental Analysis: C, 48.93; H, 5.34; Cl, 7.22; F, 11.61; N, 17.12; O, 9.78

Price and Availability

Size	Price	Availability
1mg	USD 360.00	2 Weeks
5mg	USD 750.00	2 Weeks
10mg	USD 1,125.00	2 Weeks
25mg	USD 1,800.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PKCθ Inhibitor HCl; PKCθ Inhibitor Hydrochloride; Protein Kinase C θ Inhibitor

IUPAC/Chemical Name

N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitro-N2-(2-(trifluoromethoxy)benzyl)pyrimidine-2,4-diamine hydrochloride

InChi Key

DAMOOQKWLUXEGI-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H25F3N6O3.ClH/c21-20(22,23)32-17-4-2-1-3-15(17)11-26-19-27-12-16(29(30)31)18(28-19)25-10-14-7-5-13(9-24)6-8-14;/h1-4,12-14H,5-11,24H2,(H2,25,26,27,28);1H

SMILES Code

NCC1CCC(CNC2=NC(NCC3=C(C=CC=C3)OC(F)(F)F)=NC=C2[N+]([O-])=O)CC1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	1.0	2.04

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 490.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Crosignani S, Campos S, Bouix-Peter C, Harris C, Talbot E, Hu H, Wang S, Maclean J, Zanelli U, Taylor S, Foote K, Hacini-Rachinel F, Nicodeme E, Julia V. Discovery of a novel series of selective macrocyclic PKCTheta inhibitors. Bioorg Med Chem Lett. 2024 Mar 1;100:129630. doi: 10.1016/j.bmcl.2024.129630. Epub 2024 Feb 1. PMID: 38307441. 2: Agosto-Marlin IM, Nikodemova M, Dale EA, Mitchell GS. BDNF-induced phrenic motor facilitation shifts from PKCθ to ERK dependence with mild systemic inflammation. J Neurophysiol. 2023 Feb 1;129(2):455-464. doi: 10.1152/jn.00345.2022. Epub 2023 Jan 25. PMID: 36695529; PMCID: PMC9942899. 3: Al-Sabri MH, Behare N, Alsehli AM, Berkins S, Arora A, Antoniou E, Moysiadou EI, Anantha-Krishnan S, Cosmen PD, Vikner J, Moulin TC, Ammar N, Boukhatmi H, Clemensson LE, Rask-Andersen M, Mwinyi J, Williams MJ, Fredriksson R, Schiöth HB. Statins Induce Locomotion and Muscular Phenotypes in Drosophila melanogaster That Are Reminiscent of Human Myopathy: Evidence for the Role of the Chloride Channel Inhibition in the Muscular Phenotypes. Cells. 2022 Nov 8;11(22):3528. doi: 10.3390/cells11223528. PMID: 36428957; PMCID: PMC9688544. 4: Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazzieri R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers (Basel). 2022 Mar 21;14(6):1596. doi: 10.3390/cancers14061596. PMID: 35326747; PMCID: PMC8946217. 5: Kutzner K, Woods S, Karayel O, Gehring T, Yin H, Flatley A, Graß C, Wimberger N, Tofaute MJ, Seeholzer T, Feederle R, Mann M, Krappmann D. Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. Sci Signal. 2022 Mar;15(723):eabk3083. doi: 10.1126/scisignal.abk3083. Epub 2022 Mar 1. PMID: 35230873. 6: Morroni J, Schirone L, Valenti V, Zwergel C, Riera CS, Valente S, Vecchio D, Schiavon S, Ragno R, Mai A, Sciarretta S, Lozanoska-Ochser B, Bouchè M. Inhibition of PKCθ Improves Dystrophic Heart Phenotype and Function in a Novel Model of DMD Cardiomyopathy. Int J Mol Sci. 2022 Feb 18;23(4):2256. doi: 10.3390/ijms23042256. PMID: 35216371; PMCID: PMC8880527. 7: Papa P, Whitefield B, Mortensen DS, Cashion D, Huang D, Torres E, Parnes J, Sapienza J, Hansen J, Correa M, Delgado M, Harris R, Hegde S, Norris S, Bahmanyar S, Plantevin-Krenitsky V, Liu Z, Leftheris K, Kulkarni A, Bennett B, Hur EM, Ringheim G, Khambatta G, Chan H, Muir J, Blease K, Burnett K, LeBrun L, Morrison L, Celeridad M, Khattri R, Cathers BE. Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005. J Med Chem. 2021 Aug 26;64(16):11886-11903. doi: 10.1021/acs.jmedchem.1c00388. Epub 2021 Aug 6. PMID: 34355886. 8: Velnati S, Centonze S, Girivetto F, Baldanzi G. Diacylglycerol Kinase alpha in X Linked Lymphoproliferative Disease Type 1. Int J Mol Sci. 2021 May 29;22(11):5816. doi: 10.3390/ijms22115816. PMID: 34072296; PMCID: PMC8198409. 9: Wang L, Liu G, Wu N, Dai B, Han S, Liu Q, Huang F, Chen Z, Xu W, Xia D, Gao C. mTOR regulates GPVI-mediated platelet activation. J Transl Med. 2021 May 10;19(1):201. doi: 10.1186/s12967-021-02756-y. PMID: 33971888; PMCID: PMC8111939. 10: Nicolle A, Zhang Y, Belguise K. The Emerging Function of PKCtheta in Cancer. Biomolecules. 2021 Feb 5;11(2):221. doi: 10.3390/biom11020221. PMID: 33562506; PMCID: PMC7915540. 11: Wang J, Jin W, Zhou X, Li J, Xu C, Ma Z, Wang J, Qin L, Zhou B, Ding W, Gao T, Yao H, Chen Z. Identification, Structure-Activity Relationships of Marine- Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy. J Med Chem. 2020 Nov 12;63(21):12978-12991. doi: 10.1021/acs.jmedchem.0c01271. Epub 2020 Oct 25. PMID: 33100009. 12: da Silva Rosa SC, Martens MD, Field JT, Nguyen L, Kereliuk SM, Hai Y, Chapman D, Diehl-Jones W, Aliani M, West AR, Thliveris J, Ghavami S, Rampitsch C, Dolinsky VW, Gordon JW. BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA/PKA phosphorylation. Autophagy. 2021 Sep;17(9):2257-2272. doi: 10.1080/15548627.2020.1821548. Epub 2020 Oct 12. PMID: 33044904; PMCID: PMC8496715. 13: Byerly JH, Port ER, Irie HY. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim. Breast Cancer Res. 2020 Jun 29;22(1):72. doi: 10.1186/s13058-020-01302-w. PMID: 32600444; PMCID: PMC7322866. 14: De la Torre-Tarazona HE, Jiménez R, Bueno P, Camarero S, Román L, Fernández- García JL, Beltrán M, Nothias LF, Cachet X, Paolini J, Litaudon M, Alcami J, Bedoya LM. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochem Pharmacol. 2020 Jul;177:113937. doi: 10.1016/j.bcp.2020.113937. Epub 2020 Mar 26. PMID: 32224142. 15: Han C, Lei D, Liu L, Xie S, He L, Wen S, Zhou H, Ma T, Li S. Morphine induces the differentiation of T helper cells to Th2 effector cells via the PKC- θ-GATA3 pathway. Int Immunopharmacol. 2020 Mar;80:106133. doi: 10.1016/j.intimp.2019.106133. Epub 2020 Jan 20. PMID: 31931364. 16: Rashidi A, Miska J, Lee-Chang C, Kanojia D, Panek WK, Lopez-Rosas A, Zhang P, Han Y, Xiao T, Pituch KC, Kim JW, Talebian M, Fares J, Lesniak MS. GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma. Cancer Immunol Immunother. 2020 Jan;69(1):81-94. doi: 10.1007/s00262-019-02441-6. Epub 2019 Dec 16. PMID: 31844909; PMCID: PMC6952559. 17: Zhuang M, Song M, Liu D, Huang J, Sun B. Exogenous carbon monoxide suppresses LPS-Induced platelet SNAREs complex assembly and α-granule exocytosis via integrin αIIbβ3-Mediated PKCθ/Munc18a pathway. Exp Cell Res. 2020 Jan 15;386(2):111735. doi: 10.1016/j.yexcr.2019.111735. Epub 2019 Nov 18. PMID: 31751554. 18: Chuang HC, Tan TH. MAP4K3/GLK in autoimmune disease, cancer and aging. J Biomed Sci. 2019 Oct 22;26(1):82. doi: 10.1186/s12929-019-0570-5. PMID: 31640697; PMCID: PMC6806545. 19: Collier PN, Twin HC, Knegtel RMA, Boyall D, Brenchley G, Davis CJ, Keily S, Mak C, Miller A, Pierard F, Settimo L, Bolton CM, Chiu P, Curnock A, Doyle E, Tanner AJ, Jimenez JM. Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis. ACS Med Chem Lett. 2019 Jun 27;10(8):1134-1139. doi: 10.1021/acsmedchemlett.9b00134. PMID: 31417666; PMCID: PMC6693473. 20: Li M, Zhao Y, He J, Deng W, Cheng L, Jiang Z, Wang D. Protein Kinase C Theta Inhibition Attenuates Lipopolysaccharide-Induced Acute Lung Injury through Notch Signaling Pathway via Suppressing Th17 Cell Response in Mice. Inflammation. 2019 Dec;42(6):1980-1989. doi: 10.1007/s10753-019-01058-2. PMID: 31297750.